Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Oncoproteomics: current trends and future perspectives.

William C S Cho1, Christopher H K Cheng

  • 1Queen Elizabeth Hospital, Department of Clinical Oncology, Kowloon, Hong Kong SAR, PR China. chocs@ha.org.hk

Expert Review of Proteomics
|June 8, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Cell avidity in CAR-T cell therapy.

Expert review of molecular diagnostics·2025
Same author

Differential involvement of cAMP/PKA-, PLC/PKC- and Ca<sup>2+</sup>/calmodulin-dependent pathways in GnRH-induced prolactin secretion and gene expression in grass carp pituitary cells.

Frontiers in endocrinology·2024
Same author

Circumvention of Gefitinib Resistance by Repurposing Flunarizine via Histone Deacetylase Inhibition.

ACS pharmacology & translational science·2023
Same author

The Global, Regional, and National Burden of Adult Lip, Oral, and Pharyngeal Cancer in 204 Countries and Territories: A Systematic Analysis for the Global Burden of Disease Study 2019.

JAMA oncology·2023
Same author

Comparison of Clinical Outcomes, Pathologic Characteristics, and Immune-Related Features of Postradiation vs Sporadic Oral Cavity Squamous Cell Carcinoma.

JAMA network open·2023
Same author

Repurposing of triamterene as a histone deacetylase inhibitor to overcome cisplatin resistance in lung cancer treatment.

Journal of cancer research and clinical oncology·2023
Same journal

Unveiling the post translational modification code in Alzheimer's pathogenesis: crosstalk between phosphorylation and acetylation.

Expert review of proteomics·2026
Same journal

Plasma proteome profiles of standard-risk and high-risk childhood acute lymphoblastic leukemia.

Expert review of proteomics·2026
Same journal

Potential proteomic biomarkers for monitoring clinical studies in Duchenne/Becker muscular dystrophy.

Expert review of proteomics·2026
Same journal

Proteomics-based approaches to neutrophil biology.

Expert review of proteomics·2026
Same journal

Deciphering mitochondrial metabolic vulnerabilities in ovarian clear cell carcinoma with mass spectrometry-based clinical proteomics.

Expert review of proteomics·2026
Same journal

The proteomic origin of the genetic code.

Expert review of proteomics·2026
See all related articles

Oncoproteomics uses advanced proteomics to find cancer biomarkers and drug targets. Despite challenges with complex samples, it offers great promise for understanding tumor behavior and improving cancer treatment outcomes.

Area of Science:

  • Oncoproteomics
  • Cancer Research
  • Proteomics

Background:

  • Functional proteomics aids in identifying cancer biomarkers and therapeutic targets.
  • Recent proteomics advancements enable new avenues for tumor-associated biomarker discovery.

Purpose of the Study:

  • To review the development and advancements in oncoproteomics technologies for cancer research.
  • Highlight the potential of oncoproteomics in understanding tumorigenesis and tumor behaviors.

Main Methods:

  • Application of proteomics technologies in oncology.
  • Utilizing quantitative proteomic methods, high-resolution mass spectrometry, and protein arrays.
  • Employing advanced bioinformatics for data handling and interpretation.

Main Results:

Related Experiment Videos

  • New and improved proteomics technologies facilitate biomarker discovery for predicting cancer management outcomes.
  • Oncoproteomics can unveil complex molecular events in tumorigenesis.
  • Potential to understand tumor behaviors like metastasis, invasion, and therapy resistance.

Conclusions:

  • Oncoproteomics holds significant promise for advancing cancer research and treatment.
  • Despite challenges with complex biological mixtures, oncoproteomics technologies are rapidly evolving.
  • Continued development is crucial for unlocking the full potential of oncoproteomics in oncology.